Related Experiment Videos
Bronchial hyperresponsiveness to methacholine in patients with impaired left ventricular function
L R Cabanes1, S N Weber, R Matran
1Department of Physiology, Université René Descartes, Hôpital Cochin, Paris, France.
The New England Journal of Medicine
|May 18, 1989
Summary
Patients with heart failure often experience bronchospasm due to bronchial hyperresponsiveness. This study suggests alpha-adrenergic agonists may help manage this condition by constricting bronchial vessels.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Bronchospasm and wheezy dyspnea are common in congestive heart failure (CHF).
- The underlying mechanisms of bronchospasm in CHF are not fully understood.
- Impaired left ventricular function is a key feature of CHF.
Purpose of the Study:
- To investigate the pathogenesis of bronchospasm in patients with CHF.
- To determine the role of bronchial hyperresponsiveness in CHF-related respiratory symptoms.
- To explore potential therapeutic targets for managing bronchospasm in CHF.
Main Methods:
- Studied 23 patients with chronic left ventricular dysfunction.
- Assessed bronchial hyperresponsiveness using methacholine challenge tests.
- Evaluated the effects of bronchodilators (albuterol) and alpha-adrenergic agents (methoxamine, phentolamine).
Main Results:
- 21 out of 23 patients with impaired left ventricular function showed marked bronchial hyperresponsiveness.
- Bronchial hyperresponsiveness was similar to that observed in asthma patients.
- Alpha-adrenergic agonist methoxamine prevented methacholine-induced bronchoconstriction, an effect blocked by phentolamine.
Conclusions:
- Bronchial hyperresponsiveness to cholinergic agonists is frequent in patients with impaired left ventricular function.
- This hyperresponsiveness may contribute to wheezy dyspnea in heart failure patients.
- Bronchoconstriction in CHF might involve bronchial vessel dilatation, potentially mediated by alpha-adrenergic pathways.